Results 211 to 220 of about 681,540 (349)

End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)

open access: yesEuropean Journal of Heart Failure, EarlyView.
End‐organ protective effect of serelaxin in patients with acute heart failure. CV, cardiovascular; HF, heart failure; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide. Abstract Aims Serelaxin is recombinant human relaxin‐2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy.
Adriaan A. Voors   +12 more
wiley   +1 more source

Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock

open access: yesEuropean Journal of Heart Failure, EarlyView.
Predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) in patients with cardiogenic shock. RRT, renal replacement therapy. Abstract Aims This study aimed to investigate incidence and predictors of weaning failure and in‐hospital death after successful weaning from veno‐arterial extracorporeal membrane oxygenation
Angela Dettling   +38 more
wiley   +1 more source

How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
Linking guideline‐directed medical therapy (GDMT) implementation and appropriate polypharmacy management in heart failure (HF). Polypharmacy can represent a barrier to the proper implementation of life‐prolonging GDMT for HF. A reasonable balance between the optimization of GDMT and avoiding inappropriate polypharmacy is mandatory in the contemporary ...
Davide Stolfo   +27 more
wiley   +1 more source

Phoenix Sepsis Criteria in Critically Ill Children: Retrospective Validation Using a United States Nine-Center Dataset, 2012-2018. [PDF]

open access: yesPediatr Crit Care Med
Sanchez-Pinto LN   +10 more
europepmc   +1 more source

The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice.
Giuseppe M.C. Rosano   +20 more
wiley   +1 more source

Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few
Gianluigi Savarese   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy